// our company

About eTheRNA

Advanced Technology Boosting Immunotherapy

eTheRNA immunotherapies is driving mRNA technology and therapeutic product development to deliver an innovative generation of RNA chemistries, RNA process technologies and a new and advanced generation of therapeutic and vaccine products. eTheRNA uses its established R&D foundations and in-house GMP manufacturing facilities and builds on its proprietary mRNA, mRNA adjuvant and mRNA formulation platforms to progress technology innovation and product development.

eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology.

// OUR COMPANY

What We Do

eTheRNA’s goal is to commercialize mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases.

LEARN MORE

Immunotherapies

eTheRNA builds on more than 30 years of research grade mRNA manufacturing, and more than 5 years of GMP mRNA production.

LEARN MORE

Contract Manufacturing

// Stay up to date

Newsroom

// 27 July 2021

eTheRNA immunotherapies appoints Mathieu Lane as Chief Financial Officer and President of eTheRNA Inc. located in the U.S.A.

Niel (Belgium)

eTheRNA immunotherapies NV (‘eTheRNA’ or the ‘Company’), a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, today announced that it has appointed Mathieu Lane as Chief Financial Officer and President of eTheRNA Inc., its newly established U.S. subsidiary company.

Discover all news articles

// Our company